ENTA – Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc.ENTA
$11.35Name : Enanta Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $330,039,616.00
EPSttm : -2.6
Enanta Pharmaceuticals, Inc.
$11.35
2.53%$0.28
ENTA — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
7.98
Margin Of Safety %
Put/Call OI Ratio
1.08
EPS Next Q Diff
-0.15
EPS Last/This Y
1.9
EPS This/Next Y
-0.02
Price
11.34
Target Price
20.62
Analyst Recom
1.38
Performance Q
-18.64
Upside
-898.7%
Beta
1.02
Ticker: ENTA
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-05-11 | ENTA | 15.48 | 0.60 | 1.70 | 1007 |
| 2026-05-12 | ENTA | 14.6 | 0.62 | 999.99 | 1030 |
| 2026-05-13 | ENTA | 14.04 | 0.62 | 999.99 | 1030 |
| 2026-05-14 | ENTA | 13.8 | 0.62 | 0.25 | 1029 |
| 2026-05-15 | ENTA | 13.44 | 0.60 | 0.04 | 1062 |
| 2026-05-18 | ENTA | 13.41 | 0.60 | 0.10 | 1062 |
| 2026-05-19 | ENTA | 13.79 | 0.17 | 0.01 | 570 |
| 2026-05-20 | ENTA | 13.61 | 0.17 | 0.01 | 570 |
| 2026-05-21 | ENTA | 13.82 | 0.14 | 10.00 | 687 |
| 2026-05-22 | ENTA | 13.98 | 0.14 | 2.67 | 688 |
| 2026-05-26 | ENTA | 13.51 | 0.14 | 2.67 | 688 |
| 2026-05-27 | ENTA | 13.17 | 0.15 | 19.00 | 696 |
| 2026-05-28 | ENTA | 13.2 | 0.15 | 19.00 | 696 |
| 2026-05-29 | ENTA | 13.14 | 0.18 | 90.00 | 716 |
| 2026-06-02 | ENTA | 12.02 | 1.25 | 1.46 | 1387 |
| 2026-06-03 | ENTA | 11.26 | 1.28 | 0.58 | 1478 |
| 2026-06-04 | ENTA | 11.76 | 1.23 | 0.91 | 1558 |
| 2026-06-05 | ENTA | 11.27 | 1.20 | 6.25 | 1559 |
| 2026-06-08 | ENTA | 11.1 | 1.22 | 0.26 | 1597 |
| 2026-06-09 | ENTA | 11.37 | 1.08 | 0.91 | 1696 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-05-11 | ENTA | 15.48 | 54.0 | - | -2.04 |
| 2026-05-12 | ENTA | 14.51 | 54.0 | - | -2.04 |
| 2026-05-13 | ENTA | 14.03 | 54.0 | - | -2.04 |
| 2026-05-14 | ENTA | 13.76 | 54.0 | - | -2.04 |
| 2026-05-15 | ENTA | 13.39 | 54.0 | - | -2.40 |
| 2026-05-18 | ENTA | 13.45 | 57.7 | - | -2.21 |
| 2026-05-19 | ENTA | 13.77 | 57.7 | - | -2.21 |
| 2026-05-20 | ENTA | 13.61 | 36.1 | - | -2.21 |
| 2026-05-21 | ENTA | 13.84 | 36.1 | - | -2.21 |
| 2026-05-22 | ENTA | 13.95 | 36.1 | - | -1.94 |
| 2026-05-26 | ENTA | 13.48 | 36.1 | - | -1.94 |
| 2026-05-27 | ENTA | 13.20 | 36.1 | - | -1.94 |
| 2026-05-28 | ENTA | 13.22 | 36.1 | - | -1.94 |
| 2026-05-29 | ENTA | 13.15 | 36.1 | - | -1.94 |
| 2026-06-01 | ENTA | 12.68 | 46.8 | - | -1.94 |
| 2026-06-02 | ENTA | 12.02 | 46.8 | - | -1.94 |
| 2026-06-03 | ENTA | 11.26 | 46.8 | - | -1.94 |
| 2026-06-04 | ENTA | 11.76 | 46.8 | - | -1.94 |
| 2026-06-05 | ENTA | 11.26 | 46.8 | - | -1.94 |
| 2026-06-08 | ENTA | 11.09 | 46.8 | - | -1.94 |
| 2026-06-09 | ENTA | 11.34 | 46.8 | - | -1.94 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-05-11 | ENTA | -0.86 | 15.70 | 7.63 |
| 2026-05-12 | ENTA | -0.86 | 15.70 | 7.83 |
| 2026-05-13 | ENTA | -0.86 | 15.70 | 7.83 |
| 2026-05-14 | ENTA | -0.86 | 15.70 | 7.83 |
| 2026-05-15 | ENTA | -0.86 | 15.70 | 7.83 |
| 2026-05-18 | ENTA | -0.86 | 15.60 | 7.81 |
| 2026-05-19 | ENTA | -0.86 | 15.60 | 7.81 |
| 2026-05-20 | ENTA | -0.86 | 15.60 | 7.81 |
| 2026-05-21 | ENTA | -0.86 | 15.60 | 7.81 |
| 2026-05-22 | ENTA | -0.86 | 15.60 | 7.81 |
| 2026-05-26 | ENTA | -0.86 | 0.81 | 7.81 |
| 2026-05-27 | ENTA | -0.86 | 0.81 | 7.81 |
| 2026-05-28 | ENTA | -0.86 | 0.81 | 7.98 |
| 2026-05-29 | ENTA | -0.86 | 0.81 | 7.98 |
| 2026-06-02 | ENTA | -0.86 | 0.15 | 7.98 |
| 2026-06-03 | ENTA | -0.86 | 0.15 | 7.98 |
| 2026-06-04 | ENTA | -0.82 | 0.15 | 7.98 |
| 2026-06-05 | ENTA | -0.82 | 0.15 | 7.98 |
| 2026-06-08 | ENTA | 0.00 | 0.15 | 7.98 |
| 2026-06-09 | ENTA | 0.00 | 0.15 | 7.98 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.45
Avg. EPS Est. Current Quarter
-0.45
Avg. EPS Est. Next Quarter
-0.6
Insider Transactions
Institutional Transactions
0.15
Beta
1.02
Average Sales Estimate Current Quarter
17
Average Sales Estimate Next Quarter
17
Fair Value
Quality Score
29
Growth Score
26
Sentiment Score
39
Actual DrawDown %
88.9
Max Drawdown 5-Year %
-95.6
Target Price
20.62
P/E
Forward P/E
PEG
P/S
4.77
P/B
2.83
P/Free Cash Flow
EPS
-2.59
Average EPS Est. Cur. Y
-1.94
EPS Next Y. (Est.)
-1.96
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-89.56
Relative Volume
0.77
Return on Equity vs Sector %
-80.7
Return on Equity vs Industry %
-64.5
EPS 1 7Days Diff
-1.9
EPS 1 30Days Diff
0.1
EBIT Estimation
◆
ENTA
Healthcare
$11.35
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
32.5
Range 1M
11.6%
Sup Dist
10%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
40.7%
EPS NY
23%
52W%
46.8%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+81.7% upside
Upside
+81.7%
Quality
29
Enanta Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 120
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
ENTA
Latest News
—
Caricamento notizie per ENTA…
stock quote shares ENTA – Enanta Pharmaceuticals Inc Stock Price stock today
news today ENTA – Enanta Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ENTA – Enanta Pharmaceuticals Inc yahoo finance google finance
stock history ENTA – Enanta Pharmaceuticals Inc invest stock market
stock prices ENTA premarket after hours
ticker ENTA fair value insiders trading